Syros Pharmaceuticals Shares Plummet Premarket After Study ...
2 days ago · Shares of Syros Pharmaceuticals collapsed in premarket trading Wednesday after the biopharmaceutical company's lead asset, tamibarotene, failed in a late-stage study in a rare blood cancer. Syros ...
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C ...
1 day ago · Syros Pharmaceuticals trading halted, news pending. H.C. Wainwright downgraded Syros Pharmaceuticals (SYRS) to Neutral from Buy with a price target of $1, down from $6, after the company announced ...
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the SELECT-MDS-1 Phase 3 trial evaluating tamibarotene in combination with azacitidine in newly diagnosed higher-risk ...
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial ...
3 days ago · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
Syros Pharmaceuticals, Inc. (SYRS) Stock Price, News, Quote ...
Find the latest Syros Pharmaceuticals, Inc. (SYRS) stock quote, history, news and other vital information to help you with your stock trading and investing.
Syros Pharmaceuticals, Inc. (SYRS) Latest Stock News ...
Get the latest Syros Pharmaceuticals, Inc. (SYRS) stock news and headlines to help you in your trading and investing decisions.
Press Releases :: Syros Pharmaceuticals, Inc. (SYRS)
3 days ago · Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression